查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球输液器市场
市场调查报告书
商品编码
1217641

2023-2030 年全球输液器市场

Global Infusion Sets Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

输液器将您的胰岛素泵输送装置连接到您的身体。 输液器将您的胰岛素泵连接到您的身体，并像静脉输液管一样工作。 针通常放置在插管中，插管是放置在皮下脂肪中的小塑料管。 需要这根针刺穿皮肤才能插入该装置。

市场动态

在整个预测期内，糖尿病患者人数的增加、市场的发展以及各机构在抗击糖尿病方面不断加大的努力正在推动全球输液器市场的增长。

糖尿病患者人数的增加和市场开发的进步将在预测期内推动全球输液器市场。

全球糖尿病患病率上升正在推动全球市场的增长。 例如，根据国际糖尿病联合会的数据，到 2021 年，将有超过 5.37 亿成年人患有糖尿病，全球每 10 人中就有 1 人患有糖尿病。 据估计，到 2030 年将增加到 6.43 亿，到 2045 年将增加到 7.83 亿。 四分之三的成人糖尿病患者生活在低收入和中等收入国家。 到 2021 年，糖尿病将每 5 秒夺走 1 人的生命，全球死亡人数将超过 670 万。 2021 年全球糖尿病医疗支出约为 9660 亿美元，比过去 15 年增长 316%。

超过 2.4 亿糖尿病患者未确诊，超过 5.41 亿成年人患有 2 型糖尿病，约 2100 万婴儿在怀孕期间出生时患有糖尿病。我受到影响。 此外，市场开发的增加也有助于预测期内全球市场的增长。 例如，2022 年 11 月，全球医疗保健技术领导者 Medtronic plc 宣布在美国推出首款也是唯一一款标有最长可佩戴 7 天的输液器——Medtronic Extended 输液器。 输液器是将胰岛素从胰岛素泵输送到体内的管子，通常需要每 2-3 天更换一次。 同样在 2022 年 1 月，美国食品和药物管理局 (FDA) 批准了 Capillary Biomedical (CapBio) 的研究设备豁免 (IDE)，开始对其 SteudiFlow 7 天可穿戴输液器技术进行关键试验。

产品召回阻碍了全球市场的增长。

但是，许多输液泵产品的召回预计会阻碍预测期内的市场增长。 例如，2020 年 3 月，美国食品和药物管理局宣布将 Becton Dickinson Alaris 系统输液泵召回归类为 I 类召回，这是该机构对任何可能导致严重伤害或死亡的医疗器械进行的最严格召回。这里。

COVID-19 影响分析

预计 COVID-19 的爆发将对全球输液器市场的增长产生积极影响。 例如，2020 年 5 月，美国食品和药物管理局 (FDA) 为医疗保健专业人员用于治疗因 COVID-19 感染引起的残疾而使用的输液泵和配件分配了一揽子紧急使用授权。 美国 FDA 发布了 EUA（紧急使用授权），以提高输液泵的可用性。 因此，预计在 COVID-19 大流行期间输液泵的使用增加将促进输液泵和配件的生产，从而在预测期内提振输液器市场。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 动力
      • 市场活动
      • 糖尿病患者增加
    • 约束因素
      • 产品召回
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 带过滤器
  • 没有过滤器

最终用户第 8 章

  • 医院
  • 专科诊所
  • 家庭医疗机构
  • 升序

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准

第11章公司简介

  • 美敦力公司。
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Tandem Diabetes
  • Micsafe Medical
  • Fresenius Kabi
  • Smith Medical
  • Becton, Dickinson and Company（BD）
  • B. Braun Melsungen AG
  • Baxter
  • Bexen Medical
  • Wuhan W.E.O Science & Technology

第12章 DataM

简介目录
Product Code: DMMD2824

Market Overview

The global infusion sets size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).

An infusion set links the insulin pump delivery device to the body. It operates the exact way an intravenous line does. A needle is lodged inside a cannula, a tiny plastic tube normally placed under the skin in the subcutaneous fat. This needle is required to puncture the skin to insert the set.

Market Dynamics

The rising number of diabetes patients, the growing market developments and increasing initiatives by various bodies in the fight against diabetes are boosting the global infusion set market growth throughout the forecast period.

The rising cases of diabetes and growing market developents boost the global infusion set market in the forecast period.

The growing preponderance of diabetes globally is driving the global market growth. For instance, according to the International Diabetes Federation, in 2021, over 537 million adults had diabetes, making it 1 out of 10 people globally. It is estimated to rise to 643 million by 2030 and 783 million by 2045. Also, 3 in 4 adults with diabetes are in low- and middle-income countries. In 2021 diabetes caused one death every five seconds accounting for over 6.7 million deaths globally. Globally diabetes healthcare expenditure for 2021 was around $ 966 billion accounting for a 316% rise over the last 15 years.

More than 240 million cases of diabetes are undiagnosed, over 541 million adults are on the verge of developing type 2 diabetes, and around 21 million live births are affected with diabetes during pregnancy. Furthermore, the growing market developments also contribute to the global market growth during the forecast period. For instance, in November 2022, Medtronic plc, a global leader in healthcare technology, announced the U.S. launch of the Medtronic Extended infusion set, the first and only infusion set tagged for up to 7-day wear. An infusion set is tubing that transfers insulin from an insulin pump to the body and typically requires a set change every two to three days. Also, in January 2022, The U.S. Food and Drug Administration (FDA) approved the investigational device exemption (IDE) for Capillary Biomedical (CapBio) to initiate a key trial of its SteadiFlow seven-day-wear infusion set technology.

The product recalls hinders the global market growth.

However, many infusion pump product recalls are predicted to hamper the market growth during the forecast period. For instance, in March 2020, the U.S. Food and Drug Administration announced that it had classified the Becton Dickinson Alaris System infusion pump recall as a Class I recall, the agency's most severe recall for medical devices that could cause serious injury or death.

COVID-19 Impact Analysis

The COVID-19 outbreak is anticipated to impact the global infusion set market's growth positively. For example, in May 2020, The U.S. Food and Drug Administration (FDA) allocated an umbrella emergency use approval for infusion pumps and accessories to be utilized by healthcare professionals to treat disorders caused by the COVID-19 infection. The U.S. FDA issued EUAs (Emergency Use Authorizations) that have improved the availability of infusion pumps. Therefore, the rise in infusion pump use during the COVID-19 pandemic has boosted the production of infusion pumps and accessories, which is predicted to push the infusion set market during the forecast period.

Segment Analysis

Infusion sets with filters are estimated to grow at the fastest CAGR during the forecast period (2022-2029).

Infusion filters are employed to reliably control particles from penetrating the human body, averting life-threatening blood clots, or dispersing drugs in a specific and steady pattern. The filtration/retention rate can be determined by choosing the correct pore size. By choosing the most suitable pore size, the retention rate for undersized particles can be decided, and the flow rate for the infusion solution be selected by correlating the membrane flow rate with the priming pressure of the drug delivery solution. Also, the availability of various filters ensures the dominance of the infusion sets with filter segment dominance in the forecast period. For example, the nucleopore membrane precise filtering infusion set can effectively intercept particles and play the role of filtering particles, significantly reducing the pain caused by infusion, effectively reducing the infusion reaction, and ensuring infusion safety. Also, the track-etched membranes have a highly defined pore structure and adjustable pore size and flow parameters. They can offer a unique solution for every infusion filter application. In addition, mounting can be done conveniently with ultrasonic welding or other assembly methods. These track-etched membranes come in pore sizes of 0.1 µm up to 10.0 µm and possess irradiation stability towards Gamma and X-ray for very convenient sterilization of the whole unit. Thus, the mentioned data indicates that the infusion set with filter holds most of the global infusion set market in the forecasted period.

Geographical Analysis

The North American market is expected to grow at a high CAGR during the forecast period.

The increasing cases of diabetes in North America contribute to the dominance of this region over the global market throughout the forecast period (2022-20292); for instance, the data from the American International Diabetes Federation indicates that in 2021 in North America and the Caribbean, there were 51 million adults living with diabetes which is predicted to be 57 million by 2030 and 63 million by 2045. Also, around 1 out of 4 American adults had diabetes but were undiagnosed. In 2021 diabetes claimed over 931,000 deaths and a total of $ 415 billion expenditure for diabetes. Furthermore, the increasing government initiatives to fight against diabetes also contribute to North America's dominance over the global infusion set market throughout the forecast period. For instance, in 2021, the Government of Canada announced $35 million for investments in diabetes, specifically, $25 million for diabetes research, surveillance, and prevention, as well as the development of a national framework for diabetes.

Also, expand access to the National Diabetes Prevention Program's (National DPP) lifestyle change program, an evidence-based intervention to prevent or delay the onset of type 2 diabetes in adults at high risk. The year-long program uses a CDC-approved curriculum, is facilitated by a trained lifestyle coach, and focuses on making realistic behavior changes through healthy eating, increasing physical activity, and managing stress. Thus, owing to the data mentioned the North American infusion set market is estimated to grow at a high CAGR throughout5 the forecast period.

Competitive Landscape

The growing cases of diabetes keep the global infusion sets the market competitive. Micsafe Medical, Fresenius Kabi, Smith Medical, Becton, Dickinson and Company (BD), B. Braun Melsungen AG, Baxter, Tandem Diabetes, Bexen Medical, and Wuhan W.E.O Science & Technology are examples of a few key market players. These key players hold the market through acquisitions, product launches, and collaborations. For instance, in July 2022, Tandem Diabetes Care acquired infusion set developer Capillary Biomedical.

Medtronic Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic plc has a MiniMed Mio Advance infusion set: This has a 90° soft cannula and can be inserted with only four steps. The all-in-one insertion design means that no separate serter is required.

The global infusion sets market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Market Events
      • 4.1.1.2. The Growing Cases of Diabetes
    • 4.1.2. Restraints
      • 4.1.2.1. Product Recalls
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. With Filter *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Without Filter

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Specialty Clinics
  • 8.4. Homecare Settings
  • 8.5. ASCs

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Company Profiles

  • 11.1. Medtronic Plc.
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Tandem Diabetes
  • 11.3. Micsafe Medical
  • 11.4. Fresenius Kabi
  • 11.5. Smith Medical
  • 11.6. Becton, Dickinson and Company (BD)
  • 11.7. B. Braun Melsungen AG
  • 11.8. Baxter
  • 11.9. Bexen Medical
  • 11.10. Wuhan W.E.O Science & Technology

LIST NOT EXHAUSTIVE

12. DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us